CD274 and non-small cell lung carcinoma: Because of the non‐availability of direct head‐to‐head clinical trial data, an indirect comparison approach was conducted to evaluate the efficacy of PD‐1/PD‐L1 inhibitors as first‐line treatments for advanced NSCLC with high‐level PD‐L1 expression.